Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Many approaches to weight loss, including severe caloric restriction and even some GLP-1 medications, can lead to substantial loss of lean tissue along with fat
Clinical data from metabolic syndrome models show MOTS-c administration improves insulin sensitivity by 3040% and reduces visceral adiposity without caloric restriction
When your body has the nutrients it needs, everything works betteryour mind, your mood, and your energy
Originally developed as an anti-obesity drug candidate in the late 1990s, it has since found research applications in both metabolic studies and cartilage repair investigations
It is classified as a triple incretin receptor agonist, meaning it simultaneously targets three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
US$ 24.23
US$ 20.67
US$ 23.01
US$ 24.24
US$ 25.24
US$ 24.92
